Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd. has witnessed a notable 12.02% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a slight dip in the stock price, the pharmaceutical mid-cap’s derivatives market reveals intriguing directional bets and volume patterns that merit close analysis.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Aurobindo Pharma Ltd. has experienced a notable shift in its technical momentum, moving from a mildly bullish to a bullish trend, despite a recent downgrade in its Mojo Grade from Buy to Hold. The stock’s price action, supported by key technical indicators such as MACD, moving averages, and Bollinger Bands, suggests an improving outlook amid mixed signals from volume-based metrics and Dow Theory assessments.

Aurobindo Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent decline of 4.43% in its share price to ₹1,407.00 on 16 Jun 2026, the stock’s longer-term indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other technical parameters.

Aurobindo Pharma Ltd. has witnessed a notable 12.87% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock’s recent underperformance. This surge in open interest, coupled with volume patterns and price movements, offers critical insights into evolving market positioning and potential directional bets on the mid-cap pharmaceutical giant.

Aurobindo Pharma Ltd. experienced a notable decline in intraday trading on 15 Jun 2026, with the stock touching a low of Rs 1,397.5, reflecting a 5.08% drop. This downturn came despite broader market gains, as the Sensex advanced by 1.14%, highlighting sector-specific pressures and a reversal in the stock’s recent upward trend.

Aurobindo Pharma Ltd. is rated Hold by MarketsMOJO, with this rating last updated on 25 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Aurobindo Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Aurobindo Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 25 May 2026. This adjustment follows a comprehensive reassessment of the company’s quality, valuation, financial trend, and technical parameters, reflecting a more cautious stance amid flat quarterly financial performance and evolving market dynamics.

Aurobindo Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently seen its quality grade downgraded from 'Good' to 'Average' by MarketsMOJO as of 25 May 2026. This shift reflects a nuanced change in the company’s underlying business fundamentals, including key metrics such as return on equity (ROE), return on capital employed (ROCE), debt levels, and growth consistency. This article delves into the specifics of these changes, analysing what has improved and what has deteriorated, and what this means for investors.

Aurobindo Pharma Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a sharp 6.2% decline in the stock price on 22 May 2026, the pharmaceutical mid-cap’s derivatives market reveals intriguing directional bets that merit close attention from investors and analysts alike.

Aurobindo Pharma Ltd. experienced a notable intraday decline on 22 May 2026, with its share price touching a low of Rs 1462.8, down 5.41% from the previous close. This drop contrasts sharply with the broader market’s positive momentum, as the Sensex advanced by 0.5% during the same session.

Aurobindo Pharma Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 24 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date perspective on its performance and outlook.

Aurobindo Pharma Ltd., one of India's leading pharmaceutical manufacturers and amongst the world's top five producers of semi-synthetic penicillins, delivered a mixed performance in Q4 FY26 (January-March 2026), with net sales reaching a record high of ₹8,853.34 crores but consolidated net profit declining by 1.97% year-on-year to ₹921.26 crores. The ₹85,404-crore market capitalisation company witnessed its shares tumble 4.91% on May 22, 2026, trading at ₹1,470.45, as investors digested the margin compression that overshadowed the top-line expansion.